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Was to evaluate whether a person’s beliefs regarding
where control over his health lies impacts his level of
compliance. METHOD: Data were collected on 460
DVA hyperlipidemia patients in a multisite DVA phar-
maceutical care study. Patients were given Form C of the
Multidimensional Health Locus of Control (MHLC).
Form C is an 18 item general purpose, condition-specific
locus of control scale consisting of 3 sub-scales, internal/
external control, chance and powerful others. Patients
were also given the Moriski Compliance Questionnaire
at visits 1, 5 and 7, and re-fill patterns were evaluated as
measures of compliance. RESULTS: Form C explains
16.1% of the variance in compliance (R2  0.161; P 
0.05). The internal/external control subscale R2  0.017;
P  0.05; the chance subscale R2  0.025; P  0.05; and
the powerful other subscale R2  0.155; P  0.001.
CONCLUSION: It is not surprising that the chance sub-
scale played little or no role in explaining the variance in
compliance, however we did expect the internal/external
control subscale to explain part of the variance. This
leads us to question whether the empowerment of pa-
tients improves compliance. Certainly, the impact of the
powerful others subscale suggests the opposite to be the
case. Patients with a high level of “powerful other” con-
trol were more likely to be compliant.
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Studies have demonstrated that subspecialists (SUBS)
provide better quality care when working within their
subspecialty as compared to primary care physicians
(PCPs). However, many SUBS care for patients outside of
their subspecialty. There are no data demonstrating that
SUBS treating patients outside of their specialty provide
worse care than PCPs or SUBS practicing within their
specialty. OBJECTIVES: Our purpose was to compare
the quality of care provided by SUBS practicing outside
of their subspecialty with PCPs and SUBS practicing
within their subspecialty. METHODS: We studied 5112
patients hospitalized with pneumonia (CAP), acute myo-
cardial infarction (AMI), congestive heart failure (CHF),
and upper gastrointestinal hemorrhage (UGIB) at 6 hos-
pitals in Cleveland. RESULTS: There were statistically
significant increases in severity-adjusted length of stay
(LOS) comparing SUBS practicing outside of specialty
with those practicing within specialty for patients with
CHF (23% increase, 95% CI 15%,32%), UGIB (22% in-
crease, 95% CI 7%,39%) and CAP (14% increase, 95%
CI 4%,24%). Severity-adjusted mortality (MORT) was
higher for all patients combined when comparing SUBS
outside of specialty with those within specialty (mortality
odds ratio 1.46, P  0.05). When comparing PCPs with
SUBs practicing outside of specialty, LOS was longer for
SUBs practicing outside of specialty for CHF (16% in-
crease, 95% CI 8%,26%), UGIB (15% increase, 95% CI
2%,30%), CAP (18% increase, 95% CI 9%,28%).
CONCLUSIONS: Our data suggest that SUBS caring for
patients outside of their subspecialty may have longer
LOS than SUBS practicing within specialty or PCPs, and
may have higher MORT. Our findings have implications
for health care systems where SUBS care for patients out-
side of their chosen subspecialty.
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OBJECTIVES: Most pharmacoeconomic studies concen-
trate mainly on drug costs and possibly, some additional
costs encountered in drug delivery when analysing over-
all hospital costs. Examination costs are mainly ignored
or, at best, estimated crudely. A flat rate is usually ap-
plied when calculating total therapy costs in hospitals.
METHODS: In this study, the total therapy costs of five
in-house non-surgical ENT treatments (30 patients in
each group) were calculated, with particular attention to
accurate personnel costing. Drug costs and examination
costs were examined independently. RESULTS: The total
therapy costs varied from $816 to $1562. Daily costs
varied from $170 to $186. Both examination costs and
drug costs were noted to amount to 25—28% of the total
therapy costs, but individual treatment analysis showed
wide variations in their relative contributions. For in-
stance in complicated otitis media examination costs
amounted 14.7% as compared to drug costs of 11.4%.
In contrast, in the treatment of sudden deafness, medica-
tion costs accounted for 2.5% of overall costs versus
24.6% of examination costs. CONCLUSIONS: Physi-
cians with cost responsibilities should be aware of the
differing contributions to overall costs from drug and ex-
amination costs. In detailed analysis, the relative contri-
butions from drug and examination costs can vary widely
but in our current study, the overall contribution from
these two categories was quite similar. Physicians should
be aware of the cost structure in different therapies so
that advantage may be taken of potential cost savings.
PDH10
POTENTIAL VALUE FOR MONEY OF RESEARCH: 
BETA INTERFERON AND THE UK-MS STUDY
Davies L, Smith D
Centre for Health Economics, University of York, York, UK
